BD (NYSE:BDX) announced today that it acquired self-adhesive surgical sealant film developer Tissuemed for an undisclosed amount.
Franklin Lakes, New Jersey-based BD’s acquisition of the Leeds, United Kingdom-based company aims to expand global offerings for surgeons outside the U.S. with Tissuemed’s lead product, Tissuepatch.
Tissuemed designed Tissuepatch as a proprietary sealant technology that bonds tissue to help control internal bleeding or prevent leaks from surgical incisions, according to a news release. The company said it made Tissuepatch’s thin, flexible and transparent composition ready for use out of the package, making it ideal for a range of surgical sealant applications.
BD said surgeons already trust Tissuepatch with its design for enabling strong adhesive and minimal swelling, giving the company an opportunity to leverage its reach and clinical expertise to continue making strides in sealant technologies.